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Topical tacrolimus has demonstrated efﬁcacy in vitiligo. This study compared the efﬁcacy and safety of
0.1% tacrolimus ointment with 0.1% mometasone furoate cream in adult vitiligo. We enrolled patients
with symmetrical, nonacral vitiligo, and the patients on each side were randomized to receive either 0.1%
tacrolimus ointment or 0.1% mometasone furoate cream, applied twice daily for 6 months. Repigmen-
tation outcome at 6 months was compared with baseline. Of 18 cases, 22% and 33% in tacrolimus and
mometasone groups, respectively, displayed more than 50% repigmentation (p > 0.05). Telangiectasia
was presented in one-third of cases on the mometasone-treated side. Both treatments were effective in
vitiligo; however, 0.1% tacrolimus ointment has fewer adverse effects.
Copyright © 2016, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Vitiligo is an acquired depigmentation disorder with challenging
management.1 Usually, it takes several months or years for
noticeable repigmentation. The therapeutic options depend on
vitiligo type and disease severity. For localized vitiligo, topical
corticosteroids remain the standard treatment. However, cuta-
neous side effects from long-term applications of corticosteroids,
which included skin atrophy and telangiectasia, are of major
concern. The use of topical tacrolimus, a topical calcineurin inhib-
itor, in vitiligo was ﬁrst reported in 2002.2 It is an immunomodu-
lator that affects activation and maturation of T cells, including
enhancement of melanocyte migration and differentiation, which
explain its effect on repigmentation of vitiligo.2 In the past 13 years,
the efﬁcacy of topical tacrolimus in the treatment of childhood and
adult vitiligo has been reported.2e4 Mometasone furoate is a non-
ﬂuorinated Class IV corticosteroid with a good safety proﬁle. It has ay have no ﬁnancial or non-
atter or materials discussed
y, Faculty of Medicine Siririaj
angkoknoi, Bangkok 10700,
praparut).
al Association. Published by Elsevimuch greater vasoconstriction property than hydrocortisones, but
similar adverse effects.5 Mometasone furoate 0.1% demonstrated
excellent efﬁcacy in the treatment of childhood vitiligo.6 For adult
vitiligo, mometasone is generally prescribed by physicians; how-
ever, the data of its efﬁcacy in vitiligo are still lacking. Herein, the
authors reported the outcome of a comparison study using 0.1%
tacrolimus ointment and 0.1% mometasone furoate cream for adult
vitiligo vulgaris in terms of their efﬁcacy and safety proﬁles.Methods
This study was approved by the Ethical Committee on Research
Involving Human Subjects of Siriraj Hospital, Mahidol University,
Bangkok, Thailand. The ClinicalTrials.gov identiﬁer is NCT01333410.
As this was a pilot study, 20 patients aged >18 years with
symmetrical nonacral vitiligo were enrolled. The acral areas
included hands, feet, ﬁngers, and toes. Vitiliginous sites were
selected by a simple randomization method to receive either 0.1%
tacrolimus ointment or 0.1% mometasone furoate. The participants
were asked to apply both agents twice daily for 6 months. Repig-
mentation and adverse events were recorded every 2 months.
Repigmentation outcome was assessed by two independent
dermatologists, using blinded comparative photographs taken at
baseline and 6 months. The improvement was graded as follows:er Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
N. Silpa-Archa et al. / Dermatologica Sinica 34 (2016) 177e179178no change, and 1e25%, 26e50%, 51e75%, and 76e100% repigmen-
tation.7 Repigmentation above 50% is indicated as successful
repigmentation.
Statistical analysis
All statistical calculations were performed by the statistical soft-
ware package SPSS, version 17.0 (SPSS Inc., Chicago, IL, USA). The
grading of improvements by two dermatologists was subjected to
inter-rated reliability assessment and paired sample t test.
Descriptive statistics were assessed using the Chi-square test.
Results
Eighteen participants completed the study. Two dropped out
because of inconveniences in the follow-up schedule. Demographic
data including those of age, gender, duration of vitiligo, treated
location, underlying diseases, and repigmentation outcome are
given in Table 1. In the tacrolimus group, successful repigmentation
(> 50%) was demonstrated in 22%, with 11% achieving > 75%
repigmentation, while ~50% of cases showed 1e25% repigmenta-
tion. In the mometasone group, 33% of cases gained successful
repigmentation, with 11% achieving > 75% repigmentation, while
33% of cases had 1e25% repigmentation. There was no statistically
signiﬁcant difference in the grading of repigmentation in both
groups (p ¼ 0.13); however, repigmentation of lesions on the
mometasone-treated side was achieved earlier. At 2 months,
repigmentation was seen in eight cases on the mometasone-
treated side and in three cases on the tacrolimus-treated side
(Figure 1). There was an agreement of grading improvement eval-
uated by two independent dermatologists using inter-rated reli-
ability assessment. With respect to the location, a higher
percentage of repigmentation in both groups was achieved on the
neck, followed by on the trunk and extremities. At the end of the
study, telangiectasia was found in six cases on the mometasone-
treated sites, while no case of telangiectasia was observed on theTable 1 Characteristics of the 18 vitiligo patients.
Variable Data (n ¼ 18)
Age (y)
Mean ± SD 46.8 ± 15.60
Gender
Male:female 1:17
Duration of vitiligo (mo)
Mean ± SD 25 ± 18
Underlying disease (n)
Hypothyroidism 3
Diabetes mellitus 1
Treated location (n)
for each group
Neck 6
Trunk 4
Axilla 4
Wrist 3
Knee 1
Repigmentation
(tacrolimus group) (n)
None 1e25% 26e50% 51e75% 76e100%
Neck (6) 2 1 1 1 1
Trunk (4) 3 1
Axilla (4) 4
Wrist (3) 1 2
Knee (1) 1
Repigmentation
(mometasone group) (n)
None 1e25% 26e50% 51e75% 76e100%
Neck (6) 2 1 2 1
Trunk (4) 2 2
Axilla (4) 1 2 1
Wrist (3) 1 2
Knee (1) 1
SD ¼ standard deviation.tacrolimus-treated side (p ¼ 0.03). No striae or skin atrophy was
detected in both groups. Eight (44.4%) cases and ﬁve (27.7%) cases
reported slight burning and stinging sensation on the tacrolimus-
and mometasone-treated sides, respectively. However, both agents
were well tolerated by these patients.
Discussion
Long-term treatment is usually required based upon the clinical
course of vitiligo; the ideal topical agent should have good clinical
efﬁcacy with a better safety proﬁle. Topical tacrolimus is a topical
calcineurin inhibitor derived from the bacteria Streptomyces tsu-
kubaensis. Since 2002, several studies have shown this agent to
have promising results in vitiligo. The response rates vary between
63% and 89% depending on the type and location of vitiligo, with
good results for face and neck lesions.3,8,9
Lepe et al10 conducted a double-blinded randomized trial of 0.1%
tacrolimus versus 0.05% clobetasol propionate in childhood vitiligo.
After a 2-month period, the mean repigmentation was 41.3% for
tacrolimus and 49.3% for clobetasol. Although clobetasol achieved
better repigmentation, 10% of cases had telangiectasia and 15% skin
atrophy. Mometasone furoate is one of the commonest topical
corticosteroids prescribed by physicians due to its safety proﬁle.
Kose et al6 conducted an open comparative study of topical
mometasone cream and pimecrolimus cream for childhood vitiligo.
Mometasone creamwas effective on all parts of the body; however,
pimecrolimus was effective only for the facial lesions but not for
lesions on the body areas.
To the best of our knowledge, this is the ﬁrst study comparing
the efﬁcacy and safety of 0.1% tacrolimus ointment and 0.1%
mometasone furoate cream in adult generalized vitiligo. At the end
of this study, 15 of 18 cases (83%) achieved repigmentation in both
groups, with the majority achieving 1e25% repigmentation at
6 months. Low successful response should be from the anatomical
locations that we selected in this study, which included the trunk
and wrist. Vitiligo is a difﬁcult condition to treat and usually needs
long-term treatment. A 6-month period might not be long enough
to see the maximum response to the medication. A few years may
be required to observe the maximal outcome. In addition, topical
treatments demonstrated the optimum beneﬁt in vitiligo when
combined with other treatment modalities.8,11 Moreover, topical
treatment might be considered in the maintenance phase of viti-
ligo. Cavalie et al12 reported a signiﬁcantly low relapse rate in
successfully repigmented vitiligowith twice-weekly applications of
0.1% tacrolimus ointment. Occlusive treatment may have a role in
enhancing repigmentation. Hartmann et al9 reported increasing
the efﬁcacy of topical tacrolimus in vitiligo using occlusive dressing
in areas beyond the head and neck. However, we need to be aware
of the side effects of topical steroid occlusive treatment for vitiligo.
Considering treatment response and the location of lesions, the
head and neck areas usually showamore favorable response than the
trunk and extremities because of the presence of more melanocyte
reservoirs.1 Similar to other studies, our cases achieved a higher per-
centage of repigmentation at the neck area. We had three cases with
vitiligoon thewrist area; all thesecaseshadnoorminimal response to
tacrolimus or mometasone treatment. As the wrists are close to the
hands that are known to be refractory to treatment, a surgicalmethod
or camouﬂage might be the appropriate option for this area.
Although it has been shown that mometasone has minimal
adverse events, we still observed the occurrence of telangiectasia in
one-third of cases, which is a local effect. This might be caused by
frequent applications of mometasone (twice daily). In the normal
use of mometasone in vitiligo, once-daily applications might help
reduce this adverse event. Regarding ﬁnancial aspects, mometa-
sone is inexpensive compared with tacrolimus, which is not
Figure 1 Tacrolimus-treated side at (A) baseline and (B) 6 months' follow-up. Mometasone furoate cream-treated side at (C) baseline and (D) 6 months' follow-up.
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mometasone appears to be an appropriate choice in patients for
whom tacrolimus is unaffordable.
As this is a pilot study, the limitation included the small number
of participants. A larger group is essential to conﬁrm the efﬁcacy
and safety of both agents for adult vitiligo.
In conclusion, 0.1% tacrolimus ointment and 0.1% mometasone
furoate cream are effective in the treatment of adult nonacral
vitiligo; however, topical tacrolimus has fewer adverse effects.
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